Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 6329 [2013-01977]

Download as PDF Federal Register / Vol. 78, No. 20 / Wednesday, January 30, 2013 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review The meeting announced below concerns Birth Defects Study to Evaluate Pregnancy exposureS (BD– STEPS), FOA DD13–003, initial review. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 10:00 a.m.–6:00 p.m., March 5, 2013 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Birth Defects Study to Evaluate Pregnancy exposureS (BD–STEPS), FOA DD13–003, initial review.’’ Contact Person for More Information: M. Chris Langub, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F–46, Atlanta, Georgia 30341, Telephone: (770) 488–3585, EEO6@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2013–01977 Filed 1–29–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Times and Dates: 9:00 a.m.–5:00 p.m., March 14, 2013; 9:00 a.m.–12:00 p.m., March 15, 2013. Place: CDC, Global Communications Center, Building 19, Auditorium B3, 1600 Clifton Road NE., Atlanta, Georgia, 30333. Status: Open to the public, limited only by the space available. Please register for the meeting at www.cdc.gov/hicpac. Purpose: The Committee is charged with providing advice and guidance to the Director, Division of Healthcare Quality Promotion, the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Deputy Director, Office of Infectious Diseases (OID), the Director, CDC, and the Secretary, Health and Human Services regarding: (1) The practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections (HAIs) and healthcare-related conditions. Matters To Be Discussed: The agenda will include updates on CDC’s activities for HAIs; an update on draft CDC guidelines including: guideline for prevention of infections among patients in neonatal intensive care units (NICU), guideline for the prevention of surgical site infections, and guideline for infection prevention in healthcare personnel. Also to be discussed are updates on National HealthCare Safety Network (NHSN) surveillance activities including measure development and discussion about surgical site infection definitions from the HICPAC surveillance working group. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Erin Stone, M.S., HICPAC, Division of Healthcare Quality Promotion, NCEZID, CDC, l600 Clifton Road NE., Mailstop A–07, Atlanta, Georgia 30333, Telephone (404) 639–4045. Email: hicpac@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and prevention and the Agency for Toxic Substances and Disease Registry. Healthcare Infection Control Practices Advisory Committee (HICPAC) mstockstill on DSK4VPTVN1PROD with Centers for Disease Control and Prevention Elaine L. Baker, Director, Management Analysis and Services Office Centers for Disease Control and Prevention. [FR Doc. 2013–01979 Filed 1–29–13; 8:45 am] 20:43 Jan 29, 2013 Jkt 229001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review The meeting announced below concerns Cooperative Research Agreements Related to the World Trade Center Health Program (U01) PAR 12– 126, initial review. In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Time and Date: 8:00 a.m.–5:00 p.m., March 5, 2013 (Closed). Place: CDC, Roybal Campus, Building 19 (Global Communications Center), Rooms 245/246, Atlanta, Georgia 30333, Telephone: (404) 639–4800. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters To Be Discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘Cooperative Research Agreements Related to the World Trade Center Health Program (U01) PAR 12–126.’’ Contact Person for More Information: Nina Turner, Ph.D., Scientific Review Officer, CDC/NIOSH, 1095 Willowdale Road, Mailstop G800, Morgantown, West Virginia 26505, Telephone: (304) 285–5976. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2013–01978 Filed 1–29–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention BILLING CODE 4163–18–P Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting for the aforementioned committee: VerDate Mar<15>2010 6329 PO 00000 The meeting announced below concerns Evaluation of Treatments and Services Provided to People with Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\30JAN1.SGM 30JAN1

Agencies

[Federal Register Volume 78, Number 20 (Wednesday, January 30, 2013)]
[Notices]
[Page 6329]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-01977]



[[Page 6329]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Initial Review

    The meeting announced below concerns Birth Defects Study to 
Evaluate Pregnancy exposureS (BD-STEPS), FOA DD13-003, initial review.
    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting:

    Time and Date: 10:00 a.m.-6:00 p.m., March 5, 2013 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in Section 552b(c)(4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters To Be Discussed: The meeting will include the initial 
review, discussion, and evaluation of applications received in 
response to ``Birth Defects Study to Evaluate Pregnancy exposureS 
(BD-STEPS), FOA DD13-003, initial review.''
    Contact Person for More Information: M. Chris Langub, Ph.D., 
Scientific Review Officer, CDC, 4770 Buford Highway NE., Mailstop F-
46, Atlanta, Georgia 30341, Telephone: (770) 488-3585, EEO6@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention 
and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2013-01977 Filed 1-29-13; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.